Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03897036 · ClinicalTrials.gov registry record · Phase 1
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
A Phase 1 study, sponsored by Senhwa Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT03897036 is a Phase 1 study that has completed, run by Senhwa Biosciences. The registered enrollment target is 25 participants.
The verdict
NCT03897036, a Phase 1 study, has completed, sponsored by Senhwa Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic basal cell carcinoma (BCC). The safety and tolerability of CX-4945, preliminary evidence of antitumor effect, and the effect of CX-4945 treatment on the Hh signaling pathway will also be evaluated in this study.
Interventions
- DRUG CX-4945
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2024-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03897036
The ClinicalTrials.gov registry entry for NCT03897036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senhwa Biosciences, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CX-4945 is the first listed.
NCT03897036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03897036 about?
NCT03897036 is a clinical study titled "Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)". This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in patients with locally advanced or metastatic basal cell carcinoma (BCC). The safety and tolerability of CX-4945, preli...
What is the current status of trial NCT03897036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2019-04-16. Estimated completion is 2024-01-25.
What interventions are being tested in trial NCT03897036?
The interventions under investigation include: CX-4945 (DRUG).
Who is sponsoring clinical trial NCT03897036?
This trial is sponsored by Senhwa Biosciences, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.